Entero Therapeutics (Nasdaq: ENTO)

Entero Therapeutics, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Companys programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. For more information visit www.enterothera.com. Entero Therapeutics is currently advancing a therapeutic development pipeline populated with multiple...

Gastrointestinal diseases,gastrointestinal,gi diseases,gi health,celiac,celiac disease,gluten intolerance,gluten-free diet,gluten-free,gluten,latiglutenase,gastroparesis,capeserod,lipase,pancreatitis,cystic fibrosis,adrulipase,and therapeutics

Entero therapeutics (nasdaq: ento) operates in the Pharmaceutical manufacturing industry.

Entero therapeutics (nasdaq: ento)'s revenue is 11m - 100m

Entero therapeutics (nasdaq: ento) has 11 - 50 employees.